LAEKNA-B (02105): US FDA Accepts LAE118 New Drug Clinical Trial Application

Stock News01-14

LAEKNA-B (02105) announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118. LAE118 is a novel, pan-mutant selective PI3Kα inhibitor intended for the treatment of patients with solid tumors harboring PIK3CA mutations. The company will work closely with regulatory authorities to complete the relevant application process. Building on its strong and proven track record in clinical development and the out-licensing of LAE002 (afuresertib), the company is committed to providing this precision therapy for cancer patients in need of novel treatment options. LAE118 is a novel, pan-mutant selective PI3Kα inhibitor. As a new therapeutic approach targeting PIK3CA-mutated solid tumors, the group is actively advancing this candidate drug into clinical research.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment